Key Takeaway
Both folinic acid and l-methylfolate effectively lower homocysteine in healthy adults, with folinic acid raising serum folate more but achieving equivalent homocysteine reduction, and MTHFR C677T genotype influencing treatment response.
Summary
This 2023 randomized controlled trial directly compared two active folate forms -- folinic acid and l-methylfolate -- for homocysteine lowering in 272 healthy Greek adults with baseline homocysteine at or above 10 umol/L. Both supplements were given for 3 months, with participants also genotyped for MTHFR C677T and A1298C polymorphisms.
Both groups showed significant decreases in homocysteine and increases in serum folate and cobalamin. Interestingly, folinic acid produced a considerably greater increase in serum folate levels than l-methylfolate, yet homocysteine reductions were equivalent between groups. This suggests that the relationship between serum folate and homocysteine is not strictly linear, and both folate forms are converted to the active coenzymes needed for remethylation.
The most clinically relevant finding was the influence of MTHFR genotype on treatment response. Participants with the 677TT genotype (homozygous variant) showed significantly greater homocysteine reduction than those with 677CC or 677CT genotypes. Additionally, those with the 677CT heterozygous genotype responded better to folinic acid than to l-methylfolate, challenging the common assumption that methylfolate is always superior for MTHFR variant carriers.
Methods
- Randomized controlled trial with 272 healthy Greek adults (143 men, 129 women)
- Mean age 43.0 +/- 15.3 years, baseline homocysteine >= 10 umol/L
- Group 1: folinic acid supplementation for 3 months
- Group 2: l-methylfolate supplementation for 3 months
- Participants with cobalamin < 300 pg/mL received 1 mg hydroxycobalamine IM twice weekly for first month
- MTHFR C677T and A1298C polymorphisms genotyped via PCR
- Serum folate, cobalamin, and total homocysteine measured at baseline and 3 months
Key Results
- Both groups showed significant decreases in serum total homocysteine
- Both groups showed significant increases in serum folate and cobalamin
- Folinic acid produced considerably higher serum folate increase than l-methylfolate
- No substantial difference in homocysteine reduction between the two groups
- MTHFR 677TT genotype had significantly greater homocysteine reduction vs 677CC/CT
- 677CT heterozygous genotype benefited more from folinic acid than l-methylfolate
- A1298C polymorphism did not significantly influence treatment response
Limitations
- Single-center study with Greek population, limiting generalizability
- Specific supplement dosages not detailed in abstract
- No placebo control group (compared two active treatments only)
- 3-month duration may not capture long-term effects
- Participants with low cobalamin received additional B12, which could confound results
- MTHFR genotype subgroup analyses may be underpowered